HANSOH PHARMA(03692),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

03692 HANSOH PHARMA

Market Closed 03-20 16:08:48

32.220

-0.480

-1.47%

High33.600	Low31.960	Vol6.19M
Open32.700	D1 Closing32.700	Amplitude5.02%
Mkt Cap195.09B	Tradable Cap195.09B	Total Shares6.06B
T/O201.66M	T/O Rate0.10%	Tradable Shares6.06B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"HANSOH PHARMA","latestPrice":32.22,"timestamp":1773994128005,"preClose":32.7,"halted":0,"volume":6193016,"delay":0,"changeRate":-0.014678899082568928,"floatShares":6055000000,"shares":6055000000,"eps":0.737226,"marketStatus":"Market Closed","change":-0.48,"latestTime":"03-20 16:08:48","open":32.7,"high":33.6,"low":31.96,"amount":201662460,"amplitude":0.050153,"askPrice":32.22,"askSize":18000,"bidPrice":32.2,"bidSize":12000,"shortable":3,"etf":0,"ttmEps":0.87991,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":7,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":32.7,"dividendRate":0.011387,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":0.6380194706930215,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2620786298","title":"Hansoh Pharmaceutical Group  Stock Slides 1.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786298","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620786298?lang=en_us&edition=fundamental","pubTime":"2026-03-20 16:32","pubTimestamp":1773995520,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. shed 1.5% to 32.22 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 25277.32.This was the stock's second consecutive day of losses.Hansoh Pharmaceutical Group Co. Ltd. closed 27% below its 52-week high of HK$44.22, which the company achieved Jan. 15.Trading volume totaled 6.2 million shares, compared to the 50-day average of 8.6 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","03692","BK1583","BK1191"],"gpt_icon":0},{"id":"1101092239","title":"Hansoh Pharma (03692) Sets 29 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=1101092239","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101092239?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:23","pubTimestamp":1773825794,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA, 03692) will convene a board meeting on Sunday, 29 March 2026. The agenda includes:   1) Reviewing and approving the consolidated financial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"gpt_icon":0},{"id":"2620930236","title":"Hansoh Pharmaceutical to Hold Board Meeting to Approve Annual Results and Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2620930236","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620930236?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:01","pubTimestamp":1773824461,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical will hold a board meeting on March 29, 2026 to consider and approve its final results for the year ended December 31, 2025. The board will also consider a recommendation of a final dividend at the March 29, 2026 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL925WBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1589","BK1583","BK1191"],"gpt_icon":0},{"id":"2620858872","title":"China's Biopharma Sector Expected to Receive More Government Support -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2620858872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620858872?lang=en_us&edition=fundamental","pubTime":"2026-03-18 11:12","pubTimestamp":1773803520,"startTime":"0","endTime":"0","summary":"0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the Hang Seng Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and Ali Health.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995583.HKD","LU0456827905.SGD","BK1502","LU2039709279.SGD","LU2242644610.SGD","LU2264538146.SGD","LU0456846285.SGD","LU0856984785.SGD","SG9999013486.USD","LU1934453819.USD","LU0261945553.USD","BK6523","603259","LU0516423174.USD","BK1142","LU0210637038.USD","02269","03692","BK1515","SG9999002679.SGD","LU1988902786.USD","LU0359202008.SGD","LU0516422440.USD","LU1064131342.USD","BK1615","LU0516422366.SGD","LU1794554557.SGD","SGXZ27511609.SGD","SG9999006266.SGD","IE00B0JY6N72.USD","LU0572940350.SGD","SG9999014484.SGD","BK1610","LU0819121731.USD","SG9999014492.USD","LU2152927971.USD","BK0216","LU2506951958.HKD","BK1576","01801","LU3063872942.SGD","LU0455707207.USD","LU0979878070.USD","00241","LU2495084118.USD","LU0320764599.SGD","SG9999003826.SGD","LU0588545904.SGD","LU0051755006.USD"],"gpt_icon":1},{"id":"2620442203","title":"Hansoh Pharmaceutical Group  Stock Advances 1.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442203","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620442203?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:45","pubTimestamp":1773737100,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. rallied 1.3% to 32.82 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.1% to 25868.54.The stock's rise snapped a four-day losing streak.Hansoh Pharmaceutical Group Co. Ltd. closed 26% short of its 52-week high of HK$44.22, which the company achieved Jan. 15.Trading volume totaled 10.9 million shares, compared to the 50-day average of 8.4 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1191","03692","BK1583"],"gpt_icon":0},{"id":"2619716785","title":"Hansoh Pharmaceutical Group  Stock Slides 2.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2619716785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619716785?lang=en_us&edition=fundamental","pubTime":"2026-03-13 16:43","pubTimestamp":1773391380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. slid 2.7% to 32.60 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.0% to 25465.60.This was the stock's third consecutive day of losses.Hansoh Pharmaceutical Group Co. Ltd. closed 26% short of its 52-week high of HK$44.22, which the company reached Jan. 15.Trading volume totaled 10.8 million shares, compared to the 50-day average of 8.1 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","03692","BK1191","BK1589"],"gpt_icon":0},{"id":"2618391237","title":"Hansoh Pharmaceutical Group  Stock Slips 1.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2618391237","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618391237?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:33","pubTimestamp":1773217980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. slid 1.5% to 33.64 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.2% to 25898.76.The stock's fall snapped a four-day winning streak.Hansoh Pharmaceutical Group Co. Ltd. closed 24% below its 52-week high of HK$44.22, which the company reached Jan. 15.Trading volume totaled 6.8 million shares, compared to the 50-day average of 8.0 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","BK1589","BK1583"],"gpt_icon":0},{"id":"2618671508","title":"BUZZ-Regeneron rises after announcing positive trial data on weight-loss drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2618671508","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618671508?lang=en_us&edition=fundamental","pubTime":"2026-03-10 03:40","pubTimestamp":1773085215,"startTime":"0","endTime":"0","summary":"BUZZ-Regeneron rises after announcing positive trial data on weight-loss drug** Shares of Regeneron REGN.O rises ~2% to $774.29 after the company announced positive trial results of a potential weight","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL6N3ZX1F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2362540622.SGD","LU0882574055.USD","LU0823434740.USD","LU0320765992.SGD","LU2468319806.SGD","BK4585","LU0889565916.HKD","REGN","LU0823416689.USD","LU0114720955.EUR","LU1974910355.USD","LU0109394709.USD","LU1917777945.USD","BK4588","LU0053666078.USD","BK1583","LU0823434583.USD","LU2237438978.USD","LU2023250504.SGD","BK1191","LU2106854487.HKD","03692","BK1589","BK4139","LU2089984988.USD","LU2362541273.HKD","LU2362541513.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2617944659","title":"Hansoh reports Phase 3 olatorepatide data showing up to 19.3% weight loss at 48 weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2617944659","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617944659?lang=en_us&edition=fundamental","pubTime":"2026-03-07 09:30","pubTimestamp":1772847002,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. announced positive Phase 3 results for olatorepatide , an investigational once-weekly GLP-1/GIP receptor dual agonist, in adults with obesity or overweight. In a randomized, double-blind, placebo-controlled trial  conducted at 33 sites over 48 weeks, olatorepatide met co-primary endpoints, with up to 19.3% mean body-weight loss at Week 48 and up to 97.2% of participants achieving at least 5% weight loss. The company said detailed results will be presented at an upcoming international medical conference and submitted for publication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on March 07, 2026, an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260307:nNDLbvSJyk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1191","BK1583","BK1589"],"gpt_icon":0},{"id":"2617038815","title":"Cancer Cell Publishes Phase 1 Lung Cancer Results for Hansoh’s Risvutatug Rezetecan","url":"https://stock-news.laohu8.com/highlight/detail?id=2617038815","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617038815?lang=en_us&edition=fundamental","pubTime":"2026-03-06 09:00","pubTimestamp":1772758808,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. reported that results from expansion cohorts of the ARTEMIS-001 first-in-human Phase 1a/1b trial  of risvutatug rezetecan , a B7-H3-targeted antibody-drug conjugate, in previously treated advanced solid tumors have been published in Cancer Cell. In lung cancer cohorts, confirmed objective response rates were 52.3% in extensive-stage small cell lung cancer  and 22.4% in non-small cell lung cancer , with median overall survival of 13.0 and 13.7 months, respectively; 8.0 mg/kg every three weeks was selected for Phase 3 development. The results have already been presented via publication, and the company said confirmatory Phase 3 studies in second-line SCLC are underway in China and globally, with additional pivotal lung cancer studies planned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL41Z7dS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","BK1583","BK1589"],"gpt_icon":0},{"id":"2617514201","title":"Hansoh Pharmaceutical Group  Stock Advances 1.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2617514201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617514201?lang=en_us&edition=fundamental","pubTime":"2026-03-05 16:33","pubTimestamp":1772699580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. rose 1.6% to 32.50 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.3% to 25321.34.The stock's rise snapped a three-day losing streak.Hansoh Pharmaceutical Group Co. Ltd. closed 27% short of its 52-week high of HK$44.22, which the company reached Jan. 15.Trading volume totaled 9.5 million shares, compared to the 50-day average of 7.6 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","03692","BK1589"],"gpt_icon":0},{"id":"2616109312","title":"Hansoh Pharmaceutical Group  Stock Slips 3.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2616109312","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616109312?lang=en_us&edition=fundamental","pubTime":"2026-03-03 16:32","pubTimestamp":1772526720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. slipped 3.1% to 33.28 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.1% to 25768.08.This was the stock's second consecutive day of losses.Hansoh Pharmaceutical Group Co. Ltd. closed 25% short of its 52-week high of HK$44.22, which the company achieved Jan. 15.Trading volume totaled 8.1 million shares, compared to the 50-day average of 7.7 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1589","BK1191","BK1583"],"gpt_icon":0},{"id":"1192201552","title":"Hansoh Pharma (03692) Publishes Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1192201552","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192201552?lang=en_us&edition=fundamental","pubTime":"2026-03-02 18:01","pubTimestamp":1772445696,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Company Limited reported that authorized share capital remained at HKD200,000, with no changes in the total of 20,000,000,000 authorized shares at a par value of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"gpt_icon":0},{"id":"1148570608","title":"UBS Forecasts 10% Revenue Growth for Healthcare Sector This Year, Names 3SBIO as Top Pick","url":"https://stock-news.laohu8.com/highlight/detail?id=1148570608","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148570608?lang=en_us&edition=fundamental","pubTime":"2026-03-02 14:07","pubTimestamp":1772431669,"startTime":"0","endTime":"0","summary":"UBS has released a research report projecting that the median revenue growth for rated healthcare companies will reach 16% in 2025 and 10% in 2026, based on the latest industry sales data and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","LU2039709279.SGD","LU0314109678.HKD","LU0359201885.HKD","IE00B543WZ88.USD","LU1960683339.HKD","LU1993786604.SGD","LU1152091168.USD","LU1328277881.USD","BK1521","LU1226288170.HKD","03692","IE0008368742.USD","BK1161","LU1951186391.HKD","IE00BZ08YS42.EUR","LU0072913022.USD","IE00BZ08YR35.GBP","BK4585","LU0140636845.USD","LU0067412154.USD","IE00BZ08YT58.USD","LU0359202008.SGD","BK1589","LU1226287792.SGD","LU0359201612.USD","IE0008369823.USD","LU0880133367.SGD","LU1008478684.HKD","LU0326950275.SGD","01276","LU1226287875.USD","01530","LU1226287529.USD","HK0000165453.HKD","IE00B5MMRT66.SGD","BK1583","LU1813983027.USD","XLV","IE00B031HY20.USD","LU1807302812.USD","BK1191","XBI","BK4581","LU1226288253.USD","SG9999004220.SGD","BK4588","LU1152091754.HKD","BK1593","LABU","BK1515","LU0501845795.SGD","LU2543165471.USD","159760","01093","LU0315179316.USD"],"gpt_icon":0},{"id":"2616873305","title":"Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After EU Approval For Aumolertinib Mesylate Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2616873305","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616873305?lang=en_us&edition=fundamental","pubTime":"2026-03-01 21:16","pubTimestamp":1772370964,"startTime":"0","endTime":"0","summary":"What the EU approval could mean for Hansoh Pharmaceutical Group (SEHK:3692)\nThe European Commission’s approval of Hansoh Pharmaceutical Group (SEHK:3692)’s Aumolertinib Mesylate Tablets for specific advanced non small cell lung cancer patients takes Ameile and Aumseqa beyond China and into a major new market.\nThis decision, following a positive view from the European Medicines Agency’s Committee for Medicinal Products for Human Use, adds an EU indication for both first line EGFR mutated NSCLC...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["03692","DCF","BK1583","BK1589","BK4156","BK1191"],"gpt_icon":0},{"id":"2614895895","title":"Hansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089","url":"https://stock-news.laohu8.com/highlight/detail?id=2614895895","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614895895?lang=en_us&edition=fundamental","pubTime":"2026-02-28 08:03","pubTimestamp":1772237002,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co., Ltd. reported data from two open-label studies of mocertatug rezetecan , a B7-H4-targeted antibody-drug conjugate, in heavily pretreated patients with platinum-sensitive ovarian cancer. The results were presented at ESGO 2026: a Phase 2 monotherapy poster  and a Phase 1 combination study with bevacizumab  selected for a late-breaking abstract mini-oral session. In the Phase 2 PSOC cohort, confirmed overall response rate was 64.5% at a median follow-up of 16.6 months, with median duration of response 13.8 months and median progression-free survival 14.1 months; the most common grade 3 or higher treatment-emergent adverse events were hematologic laboratory abnormalities. In the Phase 1 PSOC cohort receiving the combination, confirmed overall response rate was 72.2% at a median follow-up of 3.9 months, and no new or overlapping toxicity was reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260228:nNDL4T2ShM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","BK1589","BK1583"],"gpt_icon":0},{"id":"2614958938","title":"Hansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2614958938","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614958938?lang=en_us&edition=fundamental","pubTime":"2026-02-28 08:03","pubTimestamp":1772236994,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co., Ltd. announced that Phase 2 data for risvutatug rezetecan , a B7-H3-targeted antibody-drug conjugate, were presented at the 2026 ASCO Genitourinary Cancers Symposium. The ARTEMIS-003  open-label, multicenter study is evaluating the drug in patients with metastatic castration-resistant prostate cancer who progressed after at least one prior systemic therapy, using an 8.0 mg/kg dose every three weeks, with objective response rate assessed per combined RECIST v1.1 and PCWG3 criteria as the primary endpoint. In taxane-pretreated patients, the combined objective response rate was 38.9% and the combined PSA50 response rate was 40.7%; in taxane-nave patients, the unconfirmed objective response rate was 41.7% and the unconfirmed PSA50 rate was 23.8%, with enrollment ongoing and updated results pending. The most common grade 3 or higher treatment-related adverse events reported at an incidence of at least 20% were decreased neutrophil count and anemia.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260228:nNDL38l6xk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","03692","BK1191"],"gpt_icon":0},{"id":"1146971038","title":"Hansoh Pharmaceutical (3692) Announces NMPA Acceptance of New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1146971038","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146971038?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:25","pubTimestamp":1772195146,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Company Limited (3692) announced that on February 27, 2026, the National Medical Products Administration accepted the New Drug Application for Dalmelitinib Mesylate...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"gpt_icon":0},{"id":"2614858176","title":"Hansoh Pharmaceutical - New Drug Application of Dalmelitinib Mesylate Tablets Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2614858176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614858176?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:10","pubTimestamp":1772194241,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN193:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03692","BK1583","BK1589","BK1191"],"gpt_icon":0},{"id":"2614858170","title":"China NMPA Accepts Hansoh Dalmelitinib NDA for EGFR-Mutant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2614858170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614858170?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:10","pubTimestamp":1772194226,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. said China’s National Medical Products Administration has accepted a new drug application for dalmelitinib mesylate tablets used in combination with aumolertinib mesylate tablets  to treat patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer whose tumors have MET amplification after prior EGFR tyrosine kinase inhibitor therapy. The company said dalmelitinib  is an oral, highly selective c-MET tyrosine kinase inhibitor it developed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL8V8Wsm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1589","BK1191","BK1583"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.1268},{"period":"3month","weight":-0.1631},{"period":"6month","weight":-0.0733},{"period":"1year","weight":0.5296},{"period":"ytd","weight":-0.107}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0535},{"period":"3month","weight":-0.0161},{"period":"6month","weight":-0.0478},{"period":"1year","weight":0.0437},{"period":"ytd","weight":-0.0138}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002565},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.01282},{"month":3,"riseRate":0.285714,"avgChangeRate":0.010048},{"month":4,"riseRate":0.5,"avgChangeRate":0.03201},{"month":5,"riseRate":0.666667,"avgChangeRate":0.019349},{"month":6,"riseRate":0.666667,"avgChangeRate":0.055622},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000332},{"month":8,"riseRate":0.714286,"avgChangeRate":0.01897},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.033021},{"month":10,"riseRate":0.142857,"avgChangeRate":0.001586},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063467},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016858}],"exchange":"SEHK","name":"HANSOH PHARMA","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HANSOH PHARMA(03692),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HANSOH PHARMA(03692) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HANSOH PHARMA,03692,HANSOH PHARMA股票,HANSOH PHARMA股票老虎,HANSOH PHARMA股票老虎国际,HANSOH PHARMA行情,HANSOH PHARMA股票行情,HANSOH PHARMA股价,HANSOH PHARMA股市,HANSOH PHARMA股票价格,HANSOH PHARMA股票交易,HANSOH PHARMA股票购买,HANSOH PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HANSOH PHARMA(03692),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HANSOH PHARMA(03692) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}